Insmed Incorporated (NASDAQ:INSM) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC raised its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 52.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 71,227 shares of the biopharmaceutical company's stock after purchasing an additional 24,634 shares during the quarter. Intech Investment Management LLC's holdings in Insmed were worth $4,918,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Steward Partners Investment Advisory LLC grew its position in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 248 shares during the period. Spire Wealth Management purchased a new stake in shares of Insmed in the fourth quarter valued at about $47,000. Smartleaf Asset Management LLC increased its stake in shares of Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 411 shares during the period. Finally, Venturi Wealth Management LLC acquired a new stake in Insmed in the fourth quarter valued at about $86,000.

Wall Street Analysts Forecast Growth

INSM has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $90.00 target price on shares of Insmed in a research report on Friday, February 21st. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Truist Financial increased their price target on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. UBS Group boosted their price target on Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Finally, Guggenheim reissued a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Remove Ads

Insmed Trading Up 1.5 %

Shares of NASDAQ:INSM traded up $1.15 during midday trading on Friday, reaching $79.92. The company's stock had a trading volume of 1,928,336 shares, compared to its average volume of 2,182,816. The business has a 50 day moving average price of $77.43 and a 200 day moving average price of $73.80. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The firm has a market cap of $14.47 billion, a price-to-earnings ratio of -14.30 and a beta of 1.28. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Research analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Buying and Selling

In other news, CEO William Lewis sold 18,750 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the completion of the sale, the chief executive officer now directly owns 384,960 shares in the company, valued at $26,885,606.40. This represents a 4.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Martina M.D. Flammer sold 6,172 shares of Insmed stock in a transaction on Friday, January 10th. The shares were sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the transaction, the insider now owns 101,549 shares in the company, valued at $6,462,578.36. The trade was a 5.73 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 550,957 shares of company stock valued at $42,992,528. Insiders own 4.60% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.